Cargando…

P1196: DIFFERENT MUTATIONS IN PATIENTS WITH PRIMARY LARGE B-CELL LYMPHOMA

Detalles Bibliográficos
Autores principales:	Kamaeva, I., Lysenko, I., Nikolaeva, N., Kit, O., Novikova, I., Gaysultanova, Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430381/ http://dx.doi.org/10.1097/01.HS9.0000847648.48346.f9

Ejemplares similares

Acquired L1196M ALK mutation in anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma during alectinib administration
por: Noguchi, Kazuhiro, et al.
Publicado: (2023)

1196. Influence of antibiotic use on the effectiveness and safety of immune checkpoint inhibitors in Japan
por: Minamishima, Takuya, et al.
Publicado: (2020)

P1196: ORIENT STUDY: REGIMEN OF ORELABRUTINIB PLUS R-CHOP-LIKE FOR PATIENTS WITH NEWLY DIAGNOSED UNTREATED NON-GCB DLBCL
por: Qu, Chang-Ju, et al.
Publicado: (2023)

P1277: MUTATIONAL LANDSCAPE AND COPY NUMBER ALTERATIONS IN TESTICULAR LARGE B-CELL LYMPHOMA
por: López, C., et al.
Publicado: (2022)

P1179: EFFECTIVENESS OF CENTRAL NERVOUS SYSTEM PROPHYLAXIS STRATEGIES IN DIFFUSE LARGE B-CELL LYMPHOMA
por: Eraslan, F. Z., et al.
Publicado: (2022)

P1287: DISTINGUISHING BETWEEN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA USING THE LYMPH3CX GENE EXPRESSION PROFILING ASSAY
por: Robetorye, R. S., et al.
Publicado: (2022)

P1235: GENOTYPING ON CIRCULATING TUMOR DNA IMPROVES MUTATION DETECTION RATE IN HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA
por: Xia, Y., et al.
Publicado: (2022)

P1180: ARE EXTRANODAL LIMITED-STAGE DIFFUSE LARGE B-CELL LYMPHOMA MORE AGRESSIVE THAN NODAL FORMS?
por: Fernandes, C., et al.
Publicado: (2022)

P1286: IMPAIRED ACTIVITY OF NATURAL KILLER CELLS IN DIFFUSE LARGE B-CELL LYMPHOMA MOST LIKELY ORIGINATES FROM LYMPHOMA-INDUCED MODULATION OF THEIR SURFACE RECEPTOR EXPRESSION
por: Ringelstein-Harlev, S., et al.
Publicado: (2022)

P1205: PROGNOSTIC ROLE OF TUMOR P53 MUTATION IN DIFFUSE LARGE B CELL LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Ma, J., et al.
Publicado: (2022)

P1212: PERSONALIZED TREATMENT FOR ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
por: Nukariya, H., et al.
Publicado: (2022)

P04 Primary mediastinal large B-cell lymphoma in a Caucasian female with anti-SAE-1 positive dermatomyositis
por: Chang, Yvonne, et al.
Publicado: (2021)

P1200: RELAPSE AND OCCURRENCE OF SECOND PRIMARY MALIGNANCIES IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA IN RITUXIMAB ERA, A NATIONWIDE OBSERVATIONAL STUDY
por: Lee, H. J., et al.
Publicado: (2022)

P1292: MOLECULAR CHARACTERIZATION OF DIFFUSE LARGE B-CELL LYMPHOMA ASSOCIATED TO HEPATITIS C VIRUS INFECTION
por: Sciarra, R., et al.
Publicado: (2022)

P1175: REAL LIFE OUTCOMES OF RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA: A SINGLE CENTRE EXPERIENCE
por: Dogliotti, I., et al.
Publicado: (2022)

P1173: CLINICAL APPLICABILITY OF TARGETED NEXT-GENERATION SEQUENCING FOR PRECISION MEDICINE IN DIFFUSE LARGE B CELL LYMPHOMA
por: Huang, D., et al.
Publicado: (2022)

P1195: A PROSPECTIVE STUDY OF TARGETED SEQUENTIAL IMMUNOTHERAPY. IN PATIENTS WITH RELAPSED REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA.
por: Guo, Yuelu, et al.
Publicado: (2023)

P1164: IMAGE-BASED DETECTION OF HIGH-GRADE B CELL LYMPHOMAS (DH-L)
por: Avivi, I., et al.
Publicado: (2022)

P1731: IBRUTINIB PLUS RCHOP VERSUS RCHOP ONLY, IN YOUNG PATIENTS WITH ACTIVATED B CELL-LIKE DIFFUSE LARGE B-CELL LYMPHOMA (ABC-DLBCL): A COST EFFECTIVENESS ANALYSIS
por: Rho, H., et al.
Publicado: (2022)

P1268: DELINEATING THE NEOANTIGEN BURDEN AND TUMOUR MICROENVIRONMENT IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL).
por: Jiang, Y., et al.
Publicado: (2022)

Epidemiological Characteristics of 1196 Patients with Spinal Metastases: A Retrospective Study
por: Wang, Feng, et al.
Publicado: (2019)

1196. Environmental Contamination of Rooms of Patients Harboring Multidrug-Resistant Organisms
por: Page, Alex M, et al.
Publicado: (2022)

P1153: LONG-TERM SURVIVAL OUTCOMES OF PATIENTS WITH PRIMARY OCULAR ADNEXAL MALT LYMPHOMA: A LARGE SINGLE-CENTER COHORT STUDY
por: Liang, Y., et al.
Publicado: (2022)

P1176: CLINICAL OUTCOMES OF NOVEL THERAPIES IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
por: Crombie, Jennifer, et al.
Publicado: (2023)

P1222: PACIFIC: BRENTUXIMAB VEDOTIN AND NIVOLUMAB ALONE AND THEN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN AND PREDNISONE FOR UNTREATED PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA PATIENTS
por: Steiner, R., et al.
Publicado: (2022)

Differences in mutational signature of diffuse large B‐cell lymphomas according to the primary organ
por: Koh, Hyun‐Hee, et al.
Publicado: (2023)

P1584: CELLULAR IMMUNE RESPONSE TO THE BNT162B2 VACCINE IN LYMPHOMA PATIENTS
por: Gurion, R., et al.
Publicado: (2022)

Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis
por: Gerboth, S, et al.
Publicado: (2018)

P1155: MORE PRECISE RISK STRATIFICATION FOR TP53 MUTANT DIFFUSE LARGE B CELL LYMPHOMA
por: Du, Kai-Xin, et al.
Publicado: (2023)

P1230: PET/CT IMAGING FOR RESPONSE ASSESSMENT AND TREATMENT GUIDANCE AFTER RITUXIMAB-DOSE-ADJUSTED-EPOCH(R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL):THE GREEK EXPERIENCE ON 107 PATIENTS
por: Vassilakopoulos, T., et al.
Publicado: (2022)

P1186: A LARGE FRENCH REAL WORLD MULTICENTRIC PROSPECTIVE COHORT OF PATIENTS WITH LYMPHOMA (REALYSA STUDY): DESCRIPTION OF THE DIFFUSE LARGE B CELL LYMPHOMA PATIENTS IN REAL WORLD IN FRANCE
por: Ghesquieres, H., et al.
Publicado: (2022)

P1121: POSITRON EMISSION TOMOGRAPHY FOR FINAL RESPONSE ASSESSMENT TO RITUXIMAB-DOSE ADJUSTED EPOCH IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: WHO IS WORTHY TO BE IRRADIATED?
por: Vassilakopoulos, Theodoros, et al.
Publicado: (2023)

P1152: DEPTH OF METABOLIC RESPONSE AT INTERIM PET AND SURVIVAL OUTCOMES AMONG PATIENTS WITH PRIMARY REFRACTORY OR EARLY RELAPSING DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Bock, Allison, et al.
Publicado: (2023)

P1208: TRANSCRIPTOMIC PROFILING OF B CELL STATES AND MICROENVIROMENTAL ECOSYSTEMS REFINES THE PROGNOSTIC CLASSIFICATION OF DIFFUSE LARGE B CELL LYMPHOMA
por: Papotti, Robel, et al.
Publicado: (2023)

P1124: MOSUNETUZUMAB RETREATMENT IS EFFECTIVE AND WELL-TOLERATED IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
por: Cheah, C. Y., et al.
Publicado: (2022)

P1267: HSP110 FAVORS BCR SIGNALING THROUGH SYK PHOSPHORYLATION IN DIFFUSE LARGE B CELL LYMPHOMA
por: Cabaud Gibouin, V., et al.
Publicado: (2022)

P1211: TUMOR-ACTIVATED LYMPH NODE FIBROBLASTS SUPPRESS T CELL FUNCTION IN DIFFUSE LARGE B CELL LYMPHOMA
por: Apollonio, Benedetta, et al.
Publicado: (2023)

P1227: COMPREHENSIVE MOLECULAR SUBTYPING OF DIFFUSE LARGE B-CELL LYMPHOMA CELL LINES AND ASSOCIATION WITH TAFASITAMAB ACTIVITY
por: Arora, Arshi, et al.
Publicado: (2023)

P1163: ZANUBRUTINIB PLUS RITUXIMAB AND LENALIDOMIDE (ZR2) FOR RELAPSED AND REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
por: Zhang, Xiyuan, et al.
Publicado: (2023)

P1398: AXICABTAGENE CILOLEUCEL VERSUS TISAGENLECLEUCEL CAR-T CELLS IN RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
por: Gagelmann, Nico, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_onv4pgvteci2qhpg2njoi5eh1d